Early research (Phase 1)Active Not RecruitingNCT02879695
What this trial is testing
Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia
Who this might be right for
Recurrent B Acute Lymphoblastic LeukemiaRecurrent Mixed Phenotype Acute LeukemiaRefractory B Acute Lymphoblastic Leukemia+1 more
National Cancer Institute (NCI) 28